Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,730,000 shares, a drop of 6.1% from the August 31st total of 11,430,000 shares. Based on an average daily volume of 971,000 shares, the short-interest ratio is presently 11.1 days.
Autolus Therapeutics Price Performance
Shares of AUTL stock opened at $3.60 on Wednesday. Autolus Therapeutics has a 1 year low of $2.01 and a 1 year high of $7.45. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $3.98 and its 200-day moving average is $4.30. The firm has a market capitalization of $957.73 million, a price-to-earnings ratio of -3.00 and a beta of 2.05.
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). Sell-side analysts forecast that Autolus Therapeutics will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On Autolus Therapeutics
Wall Street Analyst Weigh In
Separately, Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.70.
Check Out Our Latest Analysis on AUTL
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
- Five stocks we like better than Autolus Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Stocks to Consider Buying in October
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Stock Market Upgrades: What Are They?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.